Chia Tai Tianqing
正大天晴
Executive Summary
Chia Tai Tianqing is a mid-tier Chinese pharmaceutical company headquartered in Lianyungang with clear BIOSECURE status, making it a viable partner for US pharma deals. The company operates in the competitive Chinese generics and specialty pharma market but lacks publicly available pipeline or leadership information, suggesting limited transparency or smaller scale operations. While BIOSECURE-compliant, the company's deal-making posture and therapeutic focus remain unclear due to limited public disclosure.
Structure: Corporate structure details are not publicly available, but as a Chinese pharma company, it likely operates through a domestic holding company structure rather than a VIE framework given its manufacturing focus. Due diligence should examine potential state ownership connections and verify the complete ownership chain given limited transparency.
BIOSECURE Risk
Company has clear BIOSECURE status with no designation under the BIOSECURE Act
Key Exposures:
- •Potential undisclosed government connections
- •Supply chain dependencies on restricted entities
Mitigation: No specific mitigation measures identified due to clear status, but ongoing monitoring recommended
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent out-licensing deals or partnerships publicly reported
Approach: Initial exploratory discussions to assess therapeutic focus and pipeline assets, with emphasis on due diligence given limited public information
Red Flags
- ⚠Limited public disclosure and transparency
- ⚠No identifiable key management team
- ⚠Unclear therapeutic focus and pipeline assets
- ⚠Potential undisclosed corporate relationships
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 0
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 0
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.